Back

The effect of CYP2C19 gene polymorphism on clinical outcomes in patients with CAD receiving antiplatelet therapy.

28 August 2017 (15:35 - 16:25)
Organised by:
Congress Presentation Part of: Remaining in the spotlight: antiplatelet agents Drug therapy ESC Premium Access ESC Congress 2017

About the speaker

Photo
Mr Wei Liu

Beijing Jishuitan Hospital, Beijing (China)

6 More presentations in this session

Presentation thumbnail
Stroke rate after twelve versus 30 month dual antiplatelet therapy in percutaneous coronary intervention patients using korean national health insurance service (nhis)
Ms S. Kang (Busan, KR)
Abstract Slides
Presentation thumbnail
Temporal trends in the use of antiplatelet therapy in patients with acute coronary syndromes
Doctor M. Esteve Pastor (Murcia, ES)
Abstract Slides
Presentation thumbnail
Efficacy and safety of perioperative aspirin therapy in non-cardiac surgery: a systematic review and comprehensive meta-analysis of randomized controlled trials
Mr G. Wolff (Ibbenbüren, DE)
Abstract Slides
Presentation thumbnail
Antiplatelet therapy and adverse outcomes in high cardiovascular risk elderly patients: a sex and gender focused analysis from REPOSI study
Doctor M. Proietti (Milan, IT)
Abstract Slides
Presentation thumbnail
Anti-platelet effect of intravenous P2Y12 receptor inhibitor cangrelor is not influenced by reticulated platelets
Doctor C. Stratz (Bad Krozingen, DE)
Abstract Slides

Access the full session

Session thumbnail
Remaining in the spotlight: antiplatelet agents

The Event

Event poster

ESC Congress 2017

28 August 2017 15:35 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources